nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CCR5—acquired immunodeficiency syndrome	0.543	1	CbGaD
Maraviroc—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0244	0.126	CbGbCtD
Maraviroc—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0229	0.119	CbGbCtD
Maraviroc—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0229	0.119	CbGbCtD
Maraviroc—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0207	0.107	CbGbCtD
Maraviroc—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0207	0.107	CbGbCtD
Maraviroc—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0179	0.0925	CbGbCtD
Maraviroc—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0174	0.0898	CbGbCtD
Maraviroc—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0157	0.0812	CbGbCtD
Maraviroc—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0157	0.0812	CbGbCtD
Maraviroc—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0151	0.0779	CbGbCtD
Maraviroc—CCR5—Binding and entry of HIV virion—CXCR4—acquired immunodeficiency syndrome	0.0113	0.15	CbGpPWpGaD
Maraviroc—CCR5—blood plasma—acquired immunodeficiency syndrome	0.00887	0.226	CbGeAlD
Maraviroc—CCR5—Binding and entry of HIV virion—CD4—acquired immunodeficiency syndrome	0.00488	0.0646	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCL3L1—acquired immunodeficiency syndrome	0.00431	0.0571	CbGpPWpGaD
Maraviroc—CCR5—Early Phase of HIV Life Cycle—CXCR4—acquired immunodeficiency syndrome	0.00416	0.0551	CbGpPWpGaD
Maraviroc—CCR5—lymphoid tissue—acquired immunodeficiency syndrome	0.00345	0.0881	CbGeAlD
Maraviroc—CCR5—digestive system—acquired immunodeficiency syndrome	0.00341	0.087	CbGeAlD
Maraviroc—CCR5—blood—acquired immunodeficiency syndrome	0.00325	0.0829	CbGeAlD
Maraviroc—CCR5—spinal cord—acquired immunodeficiency syndrome	0.00313	0.0799	CbGeAlD
Maraviroc—CCR5—vagina—acquired immunodeficiency syndrome	0.00301	0.0768	CbGeAlD
Maraviroc—CCR5—lung—acquired immunodeficiency syndrome	0.00285	0.0727	CbGeAlD
Maraviroc—CCR5—nervous system—acquired immunodeficiency syndrome	0.00264	0.0673	CbGeAlD
Maraviroc—CCR5—central nervous system—acquired immunodeficiency syndrome	0.00254	0.0648	CbGeAlD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCL4—acquired immunodeficiency syndrome	0.00236	0.0313	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CCL4—acquired immunodeficiency syndrome	0.00223	0.0296	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00209	0.0277	CbGpPWpGaD
Maraviroc—CCR5—brain—acquired immunodeficiency syndrome	0.00202	0.0514	CbGeAlD
Maraviroc—CCR5—lymph node—acquired immunodeficiency syndrome	0.00195	0.0497	CbGeAlD
Maraviroc—CCR5—Early Phase of HIV Life Cycle—CD4—acquired immunodeficiency syndrome	0.00179	0.0237	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.00177	0.0235	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00162	0.0215	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCL3—acquired immunodeficiency syndrome	0.00161	0.0214	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CCL3—acquired immunodeficiency syndrome	0.00153	0.0202	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCR2—acquired immunodeficiency syndrome	0.00146	0.0193	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCL12—acquired immunodeficiency syndrome	0.00137	0.0182	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCR4—acquired immunodeficiency syndrome	0.00137	0.0182	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—CCNT1—acquired immunodeficiency syndrome	0.00128	0.017	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00117	0.0155	CbGpPWpGaD
Maraviroc—CCR5—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.0011	0.0145	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00109	0.0144	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CCL5—acquired immunodeficiency syndrome	0.00104	0.0138	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—APOBEC3G—acquired immunodeficiency syndrome	0.00104	0.0138	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000983	0.013	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CD8A—acquired immunodeficiency syndrome	0.000973	0.0129	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000957	0.0127	CbGpPWpGaD
Maraviroc—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000894	0.0228	CbGeAlD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000889	0.0118	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—CCNT1—acquired immunodeficiency syndrome	0.000887	0.0117	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000828	0.011	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000703	0.00932	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—CXCR4—acquired immunodeficiency syndrome	0.000674	0.00894	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000659	0.00873	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000607	0.00804	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000596	0.0079	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.000578	0.00766	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CD4—acquired immunodeficiency syndrome	0.000559	0.0074	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000549	0.00727	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000516	0.00684	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000516	0.00684	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL2—acquired immunodeficiency syndrome	0.000514	0.00681	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000502	0.00665	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—CXCR4—acquired immunodeficiency syndrome	0.000466	0.00617	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000463	0.00614	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000454	0.00601	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000435	0.00577	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000435	0.00577	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00043	0.00569	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000425	0.00563	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000407	0.00539	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000404	0.00535	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000404	0.00535	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000393	0.0052	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000368	0.00488	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000346	0.00459	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000346	0.00459	CbGpPWpGaD
Maraviroc—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000344	0.00877	CbGeAlD
Maraviroc—CCR5—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000331	0.00439	CbGpPWpGaD
Maraviroc—CYP3A4—blood—acquired immunodeficiency syndrome	0.000328	0.00836	CbGeAlD
Maraviroc—CCR5—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00031	0.00411	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—CD4—acquired immunodeficiency syndrome	0.00029	0.00385	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00028	0.00372	CbGpPWpGaD
Maraviroc—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000266	0.00679	CbGeAlD
Maraviroc—CCR5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000264	0.00349	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000264	0.00349	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000263	0.00349	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000258	0.00341	CbGpPWpGaD
Maraviroc—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000256	0.00653	CbGeAlD
Maraviroc—CCR5—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000256	0.00339	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000251	0.00333	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000233	0.00309	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000218	0.00289	CbGpPWpGaD
Maraviroc—CCR5—Disease—CCNT1—acquired immunodeficiency syndrome	0.000217	0.00288	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000201	0.00266	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—CD4—acquired immunodeficiency syndrome	0.0002	0.00266	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000159	0.00211	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000158	0.0021	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000152	0.00202	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000152	0.00202	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000149	0.00197	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000149	0.00197	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000144	0.00191	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000138	0.00182	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000135	0.00179	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000135	0.00179	CbGpPWpGaD
Maraviroc—CCR5—Disease—CXCR4—acquired immunodeficiency syndrome	0.000114	0.00151	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000113	0.0015	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000112	0.00148	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000103	0.00136	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000101	0.00134	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.4e-05	0.00125	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.5e-05	0.00113	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.99e-05	0.00106	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.99e-05	0.00106	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.08e-05	0.000806	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.99e-05	0.000794	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.9e-05	0.000782	CbGpPWpGaD
Maraviroc—Myalgia—Delavirdine—acquired immunodeficiency syndrome	5.75e-05	0.000387	CcSEcCtD
Maraviroc—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	5.74e-05	0.000385	CcSEcCtD
Maraviroc—Erythema—Lamivudine—acquired immunodeficiency syndrome	5.74e-05	0.000385	CcSEcCtD
Maraviroc—Anxiety—Delavirdine—acquired immunodeficiency syndrome	5.73e-05	0.000385	CcSEcCtD
Maraviroc—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	5.7e-05	0.000383	CcSEcCtD
Maraviroc—Discomfort—Delavirdine—acquired immunodeficiency syndrome	5.68e-05	0.000382	CcSEcCtD
Maraviroc—Shock—Efavirenz—acquired immunodeficiency syndrome	5.67e-05	0.000381	CcSEcCtD
Maraviroc—Nausea—Amprenavir—acquired immunodeficiency syndrome	5.66e-05	0.000381	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	5.66e-05	0.00038	CcSEcCtD
Maraviroc—Fatigue—Zidovudine—acquired immunodeficiency syndrome	5.66e-05	0.00038	CcSEcCtD
Maraviroc—Flatulence—Lamivudine—acquired immunodeficiency syndrome	5.65e-05	0.00038	CcSEcCtD
Maraviroc—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	5.65e-05	0.00038	CcSEcCtD
Maraviroc—Tremor—Saquinavir—acquired immunodeficiency syndrome	5.63e-05	0.000379	CcSEcCtD
Maraviroc—Constipation—Zidovudine—acquired immunodeficiency syndrome	5.61e-05	0.000377	CcSEcCtD
Maraviroc—Pain—Zidovudine—acquired immunodeficiency syndrome	5.61e-05	0.000377	CcSEcCtD
Maraviroc—Asthenia—Nevirapine—acquired immunodeficiency syndrome	5.61e-05	0.000377	CcSEcCtD
Maraviroc—Syncope—Ritonavir—acquired immunodeficiency syndrome	5.6e-05	0.000376	CcSEcCtD
Maraviroc—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	5.6e-05	0.000376	CcSEcCtD
Maraviroc—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	5.59e-05	0.000376	CcSEcCtD
Maraviroc—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	5.58e-05	0.000375	CcSEcCtD
Maraviroc—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	5.56e-05	0.000374	CcSEcCtD
Maraviroc—Anaemia—Saquinavir—acquired immunodeficiency syndrome	5.56e-05	0.000373	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	5.56e-05	0.000373	CcSEcCtD
Maraviroc—Pruritus—Nevirapine—acquired immunodeficiency syndrome	5.53e-05	0.000372	CcSEcCtD
Maraviroc—Vomiting—Didanosine—acquired immunodeficiency syndrome	5.53e-05	0.000371	CcSEcCtD
Maraviroc—Insomnia—Indinavir—acquired immunodeficiency syndrome	5.52e-05	0.000371	CcSEcCtD
Maraviroc—Oedema—Delavirdine—acquired immunodeficiency syndrome	5.51e-05	0.000371	CcSEcCtD
Maraviroc—Anorexia—Efavirenz—acquired immunodeficiency syndrome	5.49e-05	0.000369	CcSEcCtD
Maraviroc—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	5.49e-05	0.000369	CcSEcCtD
Maraviroc—Rash—Didanosine—acquired immunodeficiency syndrome	5.48e-05	0.000368	CcSEcCtD
Maraviroc—Infection—Delavirdine—acquired immunodeficiency syndrome	5.48e-05	0.000368	CcSEcCtD
Maraviroc—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	5.48e-05	0.000368	CcSEcCtD
Maraviroc—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	5.48e-05	0.000368	CcSEcCtD
Maraviroc—Dermatitis—Didanosine—acquired immunodeficiency syndrome	5.48e-05	0.000368	CcSEcCtD
Maraviroc—Cough—Ritonavir—acquired immunodeficiency syndrome	5.45e-05	0.000366	CcSEcCtD
Maraviroc—Headache—Didanosine—acquired immunodeficiency syndrome	5.45e-05	0.000366	CcSEcCtD
Maraviroc—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	5.43e-05	0.000365	CcSEcCtD
Maraviroc—Shock—Delavirdine—acquired immunodeficiency syndrome	5.43e-05	0.000365	CcSEcCtD
Maraviroc—Asthenia—Stavudine—acquired immunodeficiency syndrome	5.41e-05	0.000364	CcSEcCtD
Maraviroc—Convulsion—Ritonavir—acquired immunodeficiency syndrome	5.41e-05	0.000364	CcSEcCtD
Maraviroc—Syncope—Saquinavir—acquired immunodeficiency syndrome	5.39e-05	0.000362	CcSEcCtD
Maraviroc—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	5.38e-05	0.000362	CcSEcCtD
Maraviroc—Tremor—Lamivudine—acquired immunodeficiency syndrome	5.38e-05	0.000361	CcSEcCtD
Maraviroc—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	5.36e-05	0.00036	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.36e-05	0.00071	CbGpPWpGaD
Maraviroc—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	5.36e-05	0.00036	CcSEcCtD
Maraviroc—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	5.36e-05	0.00036	CcSEcCtD
Maraviroc—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	5.35e-05	0.000359	CcSEcCtD
Maraviroc—Pruritus—Stavudine—acquired immunodeficiency syndrome	5.34e-05	0.000359	CcSEcCtD
Maraviroc—Asthenia—Abacavir—acquired immunodeficiency syndrome	5.33e-05	0.000358	CcSEcCtD
Maraviroc—Myalgia—Ritonavir—acquired immunodeficiency syndrome	5.32e-05	0.000357	CcSEcCtD
Maraviroc—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	5.3e-05	0.000356	CcSEcCtD
Maraviroc—Anaemia—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000356	CcSEcCtD
Maraviroc—Anxiety—Ritonavir—acquired immunodeficiency syndrome	5.3e-05	0.000356	CcSEcCtD
Maraviroc—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	5.29e-05	0.000355	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	5.28e-05	0.000355	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	5.27e-05	0.000354	CcSEcCtD
Maraviroc—Pruritus—Abacavir—acquired immunodeficiency syndrome	5.26e-05	0.000353	CcSEcCtD
Maraviroc—Fatigue—Indinavir—acquired immunodeficiency syndrome	5.26e-05	0.000353	CcSEcCtD
Maraviroc—Anorexia—Delavirdine—acquired immunodeficiency syndrome	5.26e-05	0.000353	CcSEcCtD
Maraviroc—Discomfort—Ritonavir—acquired immunodeficiency syndrome	5.26e-05	0.000353	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	5.25e-05	0.000353	CcSEcCtD
Maraviroc—Cough—Saquinavir—acquired immunodeficiency syndrome	5.25e-05	0.000353	CcSEcCtD
Maraviroc—Pain—Indinavir—acquired immunodeficiency syndrome	5.22e-05	0.00035	CcSEcCtD
Maraviroc—Constipation—Indinavir—acquired immunodeficiency syndrome	5.22e-05	0.00035	CcSEcCtD
Maraviroc—Insomnia—Efavirenz—acquired immunodeficiency syndrome	5.21e-05	0.00035	CcSEcCtD
Maraviroc—Convulsion—Saquinavir—acquired immunodeficiency syndrome	5.21e-05	0.00035	CcSEcCtD
Maraviroc—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	5.19e-05	0.000348	CcSEcCtD
Maraviroc—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	5.19e-05	0.000348	CcSEcCtD
Maraviroc—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	5.18e-05	0.000348	CcSEcCtD
Maraviroc—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	5.18e-05	0.000348	CcSEcCtD
Maraviroc—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	5.16e-05	0.000347	CcSEcCtD
Maraviroc—Nausea—Didanosine—acquired immunodeficiency syndrome	5.16e-05	0.000347	CcSEcCtD
Maraviroc—Syncope—Lamivudine—acquired immunodeficiency syndrome	5.15e-05	0.000346	CcSEcCtD
Maraviroc—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	5.14e-05	0.000345	CcSEcCtD
Maraviroc—Myalgia—Saquinavir—acquired immunodeficiency syndrome	5.12e-05	0.000344	CcSEcCtD
Maraviroc—Anxiety—Saquinavir—acquired immunodeficiency syndrome	5.1e-05	0.000343	CcSEcCtD
Maraviroc—Oedema—Ritonavir—acquired immunodeficiency syndrome	5.1e-05	0.000343	CcSEcCtD
Maraviroc—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	5.09e-05	0.000342	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	5.08e-05	0.000342	CcSEcCtD
Maraviroc—Discomfort—Saquinavir—acquired immunodeficiency syndrome	5.06e-05	0.00034	CcSEcCtD
Maraviroc—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	5.04e-05	0.000339	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	5.02e-05	0.000338	CcSEcCtD
Maraviroc—Shock—Ritonavir—acquired immunodeficiency syndrome	5.02e-05	0.000337	CcSEcCtD
Maraviroc—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	5.01e-05	0.000337	CcSEcCtD
Maraviroc—Cough—Lamivudine—acquired immunodeficiency syndrome	5.01e-05	0.000336	CcSEcCtD
Maraviroc—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	5.01e-05	0.000336	CcSEcCtD
Maraviroc—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	5e-05	0.000336	CcSEcCtD
Maraviroc—Dizziness—Stavudine—acquired immunodeficiency syndrome	4.99e-05	0.000335	CcSEcCtD
Maraviroc—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	4.99e-05	0.000335	CcSEcCtD
Maraviroc—Insomnia—Delavirdine—acquired immunodeficiency syndrome	4.99e-05	0.000335	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	4.98e-05	0.000334	CcSEcCtD
Maraviroc—Convulsion—Lamivudine—acquired immunodeficiency syndrome	4.97e-05	0.000334	CcSEcCtD
Maraviroc—Vomiting—Nevirapine—acquired immunodeficiency syndrome	4.97e-05	0.000334	CcSEcCtD
Maraviroc—Fatigue—Efavirenz—acquired immunodeficiency syndrome	4.97e-05	0.000334	CcSEcCtD
Maraviroc—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	4.95e-05	0.000333	CcSEcCtD
Maraviroc—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	4.95e-05	0.000333	CcSEcCtD
Maraviroc—Pain—Efavirenz—acquired immunodeficiency syndrome	4.93e-05	0.000331	CcSEcCtD
Maraviroc—Constipation—Efavirenz—acquired immunodeficiency syndrome	4.93e-05	0.000331	CcSEcCtD
Maraviroc—Rash—Nevirapine—acquired immunodeficiency syndrome	4.93e-05	0.000331	CcSEcCtD
Maraviroc—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	4.92e-05	0.000331	CcSEcCtD
Maraviroc—Dizziness—Abacavir—acquired immunodeficiency syndrome	4.92e-05	0.00033	CcSEcCtD
Maraviroc—CCR5—Disease—CD4—acquired immunodeficiency syndrome	4.91e-05	0.000651	CbGpPWpGaD
Maraviroc—Oedema—Saquinavir—acquired immunodeficiency syndrome	4.91e-05	0.00033	CcSEcCtD
Maraviroc—Headache—Nevirapine—acquired immunodeficiency syndrome	4.9e-05	0.000329	CcSEcCtD
Maraviroc—Myalgia—Lamivudine—acquired immunodeficiency syndrome	4.88e-05	0.000328	CcSEcCtD
Maraviroc—Infection—Saquinavir—acquired immunodeficiency syndrome	4.88e-05	0.000328	CcSEcCtD
Maraviroc—Anxiety—Lamivudine—acquired immunodeficiency syndrome	4.87e-05	0.000327	CcSEcCtD
Maraviroc—Anorexia—Ritonavir—acquired immunodeficiency syndrome	4.86e-05	0.000327	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	4.85e-05	0.000326	CcSEcCtD
Maraviroc—Shock—Saquinavir—acquired immunodeficiency syndrome	4.83e-05	0.000324	CcSEcCtD
Maraviroc—Discomfort—Lamivudine—acquired immunodeficiency syndrome	4.83e-05	0.000324	CcSEcCtD
Maraviroc—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	4.82e-05	0.000324	CcSEcCtD
Maraviroc—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	4.82e-05	0.000324	CcSEcCtD
Maraviroc—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	4.81e-05	0.000323	CcSEcCtD
Maraviroc—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	4.81e-05	0.000323	CcSEcCtD
Maraviroc—Vomiting—Stavudine—acquired immunodeficiency syndrome	4.8e-05	0.000322	CcSEcCtD
Maraviroc—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	4.79e-05	0.000322	CcSEcCtD
Maraviroc—Rash—Nelfinavir—acquired immunodeficiency syndrome	4.77e-05	0.000321	CcSEcCtD
Maraviroc—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	4.77e-05	0.00032	CcSEcCtD
Maraviroc—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	4.77e-05	0.00032	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	4.76e-05	0.00032	CcSEcCtD
Maraviroc—Rash—Stavudine—acquired immunodeficiency syndrome	4.76e-05	0.00032	CcSEcCtD
Maraviroc—Fatigue—Delavirdine—acquired immunodeficiency syndrome	4.75e-05	0.000319	CcSEcCtD
Maraviroc—Dermatitis—Stavudine—acquired immunodeficiency syndrome	4.75e-05	0.000319	CcSEcCtD
Maraviroc—Headache—Nelfinavir—acquired immunodeficiency syndrome	4.74e-05	0.000319	CcSEcCtD
Maraviroc—Headache—Stavudine—acquired immunodeficiency syndrome	4.73e-05	0.000318	CcSEcCtD
Maraviroc—Vomiting—Abacavir—acquired immunodeficiency syndrome	4.73e-05	0.000318	CcSEcCtD
Maraviroc—Pain—Delavirdine—acquired immunodeficiency syndrome	4.72e-05	0.000317	CcSEcCtD
Maraviroc—Constipation—Delavirdine—acquired immunodeficiency syndrome	4.72e-05	0.000317	CcSEcCtD
Maraviroc—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	4.71e-05	0.000317	CcSEcCtD
Maraviroc—Asthenia—Zidovudine—acquired immunodeficiency syndrome	4.71e-05	0.000316	CcSEcCtD
Maraviroc—Rash—Abacavir—acquired immunodeficiency syndrome	4.69e-05	0.000315	CcSEcCtD
Maraviroc—Dermatitis—Abacavir—acquired immunodeficiency syndrome	4.68e-05	0.000315	CcSEcCtD
Maraviroc—Oedema—Lamivudine—acquired immunodeficiency syndrome	4.68e-05	0.000315	CcSEcCtD
Maraviroc—Anorexia—Saquinavir—acquired immunodeficiency syndrome	4.68e-05	0.000314	CcSEcCtD
Maraviroc—Headache—Abacavir—acquired immunodeficiency syndrome	4.66e-05	0.000313	CcSEcCtD
Maraviroc—Infection—Lamivudine—acquired immunodeficiency syndrome	4.65e-05	0.000313	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	4.65e-05	0.000312	CcSEcCtD
Maraviroc—Nausea—Nevirapine—acquired immunodeficiency syndrome	4.64e-05	0.000312	CcSEcCtD
Maraviroc—Pruritus—Zidovudine—acquired immunodeficiency syndrome	4.64e-05	0.000312	CcSEcCtD
Maraviroc—Insomnia—Ritonavir—acquired immunodeficiency syndrome	4.61e-05	0.00031	CcSEcCtD
Maraviroc—Shock—Lamivudine—acquired immunodeficiency syndrome	4.61e-05	0.00031	CcSEcCtD
Maraviroc—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	4.59e-05	0.000309	CcSEcCtD
Maraviroc—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	4.58e-05	0.000308	CcSEcCtD
Maraviroc—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	4.56e-05	0.000306	CcSEcCtD
Maraviroc—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	4.56e-05	0.000306	CcSEcCtD
Maraviroc—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	4.55e-05	0.000306	CcSEcCtD
Maraviroc—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	4.51e-05	0.000303	CcSEcCtD
Maraviroc—Nausea—Nelfinavir—acquired immunodeficiency syndrome	4.5e-05	0.000302	CcSEcCtD
Maraviroc—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	4.49e-05	0.000302	CcSEcCtD
Maraviroc—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	4.49e-05	0.000302	CcSEcCtD
Maraviroc—Nausea—Stavudine—acquired immunodeficiency syndrome	4.48e-05	0.000301	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	4.47e-05	0.0003	CcSEcCtD
Maraviroc—Anorexia—Lamivudine—acquired immunodeficiency syndrome	4.46e-05	0.0003	CcSEcCtD
Maraviroc—Insomnia—Saquinavir—acquired immunodeficiency syndrome	4.44e-05	0.000298	CcSEcCtD
Maraviroc—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	4.43e-05	0.000298	CcSEcCtD
Maraviroc—Nausea—Abacavir—acquired immunodeficiency syndrome	4.42e-05	0.000297	CcSEcCtD
Maraviroc—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	4.41e-05	0.000296	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	4.4e-05	0.000296	CcSEcCtD
Maraviroc—Fatigue—Ritonavir—acquired immunodeficiency syndrome	4.4e-05	0.000295	CcSEcCtD
Maraviroc—Asthenia—Indinavir—acquired immunodeficiency syndrome	4.38e-05	0.000294	CcSEcCtD
Maraviroc—Pain—Ritonavir—acquired immunodeficiency syndrome	4.36e-05	0.000293	CcSEcCtD
Maraviroc—Constipation—Ritonavir—acquired immunodeficiency syndrome	4.36e-05	0.000293	CcSEcCtD
Maraviroc—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	4.36e-05	0.000293	CcSEcCtD
Maraviroc—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	4.36e-05	0.000293	CcSEcCtD
Maraviroc—Dizziness—Zidovudine—acquired immunodeficiency syndrome	4.34e-05	0.000291	CcSEcCtD
Maraviroc—Pruritus—Indinavir—acquired immunodeficiency syndrome	4.32e-05	0.00029	CcSEcCtD
Maraviroc—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	4.27e-05	0.000287	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	4.27e-05	0.000287	CcSEcCtD
Maraviroc—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	4.25e-05	0.000285	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	4.24e-05	0.000285	CcSEcCtD
Maraviroc—Insomnia—Lamivudine—acquired immunodeficiency syndrome	4.24e-05	0.000285	CcSEcCtD
Maraviroc—Fatigue—Saquinavir—acquired immunodeficiency syndrome	4.23e-05	0.000284	CcSEcCtD
Maraviroc—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	4.2e-05	0.000282	CcSEcCtD
Maraviroc—Pain—Saquinavir—acquired immunodeficiency syndrome	4.2e-05	0.000282	CcSEcCtD
Maraviroc—Constipation—Saquinavir—acquired immunodeficiency syndrome	4.2e-05	0.000282	CcSEcCtD
Maraviroc—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.17e-05	0.00028	CcSEcCtD
Maraviroc—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.17e-05	0.00028	CcSEcCtD
Maraviroc—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.17e-05	0.00028	CcSEcCtD
Maraviroc—Rash—Zidovudine—acquired immunodeficiency syndrome	4.14e-05	0.000278	CcSEcCtD
Maraviroc—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.14e-05	0.000278	CcSEcCtD
Maraviroc—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.13e-05	0.000278	CcSEcCtD
Maraviroc—Headache—Zidovudine—acquired immunodeficiency syndrome	4.11e-05	0.000276	CcSEcCtD
Maraviroc—Pruritus—Efavirenz—acquired immunodeficiency syndrome	4.08e-05	0.000274	CcSEcCtD
Maraviroc—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	4.07e-05	0.000273	CcSEcCtD
Maraviroc—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	4.06e-05	0.000273	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	4.04e-05	0.000272	CcSEcCtD
Maraviroc—Fatigue—Lamivudine—acquired immunodeficiency syndrome	4.04e-05	0.000271	CcSEcCtD
Maraviroc—Dizziness—Indinavir—acquired immunodeficiency syndrome	4.03e-05	0.000271	CcSEcCtD
Maraviroc—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	4.03e-05	0.000271	CcSEcCtD
Maraviroc—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	4.03e-05	0.000271	CcSEcCtD
Maraviroc—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	4.01e-05	0.00027	CcSEcCtD
Maraviroc—Constipation—Lamivudine—acquired immunodeficiency syndrome	4e-05	0.000269	CcSEcCtD
Maraviroc—Pain—Lamivudine—acquired immunodeficiency syndrome	4e-05	0.000269	CcSEcCtD
Maraviroc—Asthenia—Delavirdine—acquired immunodeficiency syndrome	3.96e-05	0.000266	CcSEcCtD
Maraviroc—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	3.94e-05	0.000265	CcSEcCtD
Maraviroc—Pruritus—Delavirdine—acquired immunodeficiency syndrome	3.9e-05	0.000262	CcSEcCtD
Maraviroc—Nausea—Zidovudine—acquired immunodeficiency syndrome	3.9e-05	0.000262	CcSEcCtD
Maraviroc—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	3.88e-05	0.000261	CcSEcCtD
Maraviroc—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	3.88e-05	0.000261	CcSEcCtD
Maraviroc—Vomiting—Indinavir—acquired immunodeficiency syndrome	3.88e-05	0.000261	CcSEcCtD
Maraviroc—Rash—Indinavir—acquired immunodeficiency syndrome	3.85e-05	0.000258	CcSEcCtD
Maraviroc—Dermatitis—Indinavir—acquired immunodeficiency syndrome	3.84e-05	0.000258	CcSEcCtD
Maraviroc—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	3.83e-05	0.000257	CcSEcCtD
Maraviroc—Headache—Indinavir—acquired immunodeficiency syndrome	3.82e-05	0.000257	CcSEcCtD
Maraviroc—Dizziness—Efavirenz—acquired immunodeficiency syndrome	3.81e-05	0.000256	CcSEcCtD
Maraviroc—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	3.77e-05	0.000254	CcSEcCtD
Maraviroc—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	3.76e-05	0.000252	CcSEcCtD
Maraviroc—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	3.7e-05	0.000249	CcSEcCtD
Maraviroc—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	3.7e-05	0.000249	CcSEcCtD
Maraviroc—Vomiting—Efavirenz—acquired immunodeficiency syndrome	3.66e-05	0.000246	CcSEcCtD
Maraviroc—Asthenia—Ritonavir—acquired immunodeficiency syndrome	3.66e-05	0.000246	CcSEcCtD
Maraviroc—Dizziness—Delavirdine—acquired immunodeficiency syndrome	3.65e-05	0.000245	CcSEcCtD
Maraviroc—Rash—Efavirenz—acquired immunodeficiency syndrome	3.63e-05	0.000244	CcSEcCtD
Maraviroc—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	3.63e-05	0.000244	CcSEcCtD
Maraviroc—Nausea—Indinavir—acquired immunodeficiency syndrome	3.62e-05	0.000243	CcSEcCtD
Maraviroc—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	3.62e-05	0.000243	CcSEcCtD
Maraviroc—Headache—Efavirenz—acquired immunodeficiency syndrome	3.61e-05	0.000243	CcSEcCtD
Maraviroc—Pruritus—Ritonavir—acquired immunodeficiency syndrome	3.61e-05	0.000242	CcSEcCtD
Maraviroc—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.52e-05	0.000237	CcSEcCtD
Maraviroc—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3.51e-05	0.000236	CcSEcCtD
Maraviroc—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	3.49e-05	0.000234	CcSEcCtD
Maraviroc—Rash—Delavirdine—acquired immunodeficiency syndrome	3.48e-05	0.000234	CcSEcCtD
Maraviroc—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	3.47e-05	0.000233	CcSEcCtD
Maraviroc—Pruritus—Saquinavir—acquired immunodeficiency syndrome	3.47e-05	0.000233	CcSEcCtD
Maraviroc—Headache—Delavirdine—acquired immunodeficiency syndrome	3.45e-05	0.000232	CcSEcCtD
Maraviroc—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	3.45e-05	0.000232	CcSEcCtD
Maraviroc—Nausea—Efavirenz—acquired immunodeficiency syndrome	3.42e-05	0.00023	CcSEcCtD
Maraviroc—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.37e-05	0.000227	CcSEcCtD
Maraviroc—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.36e-05	0.000226	CcSEcCtD
Maraviroc—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.36e-05	0.000226	CcSEcCtD
Maraviroc—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.31e-05	0.000223	CcSEcCtD
Maraviroc—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.28e-05	0.00022	CcSEcCtD
Maraviroc—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.25e-05	0.000218	CcSEcCtD
Maraviroc—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.24e-05	0.000218	CcSEcCtD
Maraviroc—Rash—Ritonavir—acquired immunodeficiency syndrome	3.22e-05	0.000216	CcSEcCtD
Maraviroc—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.21e-05	0.000216	CcSEcCtD
Maraviroc—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.2e-05	0.000215	CcSEcCtD
Maraviroc—Headache—Ritonavir—acquired immunodeficiency syndrome	3.19e-05	0.000215	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.17e-05	0.000419	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.15e-05	0.000417	CbGpPWpGaD
Maraviroc—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.12e-05	0.00021	CcSEcCtD
Maraviroc—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.1e-05	0.000208	CcSEcCtD
Maraviroc—Rash—Saquinavir—acquired immunodeficiency syndrome	3.09e-05	0.000208	CcSEcCtD
Maraviroc—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.09e-05	0.000208	CcSEcCtD
Maraviroc—Headache—Saquinavir—acquired immunodeficiency syndrome	3.07e-05	0.000207	CcSEcCtD
Maraviroc—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.03e-05	0.000204	CcSEcCtD
Maraviroc—Vomiting—Lamivudine—acquired immunodeficiency syndrome	2.98e-05	0.0002	CcSEcCtD
Maraviroc—Rash—Lamivudine—acquired immunodeficiency syndrome	2.95e-05	0.000198	CcSEcCtD
Maraviroc—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	2.95e-05	0.000198	CcSEcCtD
Maraviroc—Headache—Lamivudine—acquired immunodeficiency syndrome	2.93e-05	0.000197	CcSEcCtD
Maraviroc—Nausea—Saquinavir—acquired immunodeficiency syndrome	2.92e-05	0.000196	CcSEcCtD
Maraviroc—Nausea—Lamivudine—acquired immunodeficiency syndrome	2.78e-05	0.000187	CcSEcCtD
Maraviroc—CCR5—Disease—IL6—acquired immunodeficiency syndrome	2.66e-05	0.000352	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2e-05	0.000264	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.86e-05	0.000246	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.7e-05	0.000225	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.48e-06	4.61e-05	CbGpPWpGaD
